Gallen/Vienna Consensus suggested a high Ki-67 as a high-risk indicator that favors the addition of adjuvant chemotherapy in early HR+HER2− breast cancer but did not mention any specific PR levels being used for stratification [42]. The gene discussed is MKI67; the disease is breast carcinoma.